Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
- 7 May 2002
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 17 (5) , 887-901
- https://doi.org/10.1002/mds.10200
Abstract
Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D2/D3 dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal ganglia for the appearance of dyskinesia is unknown. We now report on the ability of repeated administration of piribedil to induce dyskinesia in drug naïve 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) ‐lesioned common marmosets compared with L‐dopa and its actions on the direct and indirect striatal outflow pathways. Administration of piribedil (4.0–5.0 mg/kg orally) or L‐dopa (12.5 mg/kg orally plus carbidopa 12.5 mg/kg orally twice daily) produced equivalent increases in locomotor activity and reversal of motor deficits over a 28‐day study period. Administration of L‐dopa resulted in the progressive development of marked dyskinesia over the period of study. In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. Surprisingly, piribedil caused an increase in vigilance and alertness compared to L‐dopa, which may relate to the recently discovered α2‐noradrenergic antagonist properties of piribedil. The behavioural differences between piribedil and L‐dopa are reflected in the biochemical changes associated with the direct striatal output pathway. Administration of L‐dopa or piribedil did not reverse the MPTP‐induced up‐regulation of preproenkephalin A mRNA in rostral or caudal areas of the putamen or caudate nucleus. In contrast, administration of either piribedil or L‐dopa reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. L‐dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment. © 2002 Movement Disorder SocietyKeywords
This publication has 74 references indexed in Scilit:
- Turning off cortical ensembles stops striatal Up states and elicits phase perturbations in cortical and striatal slow oscillations in rat in vivoThe Journal of Physiology, 2006
- Transdermal Administration of Piribedil Reverses MPTP-induced Motor Deficits in the Common MarmosetClinical Neuropharmacology, 2000
- Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesionJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Effects of neonatal 6-hydroxydopamine injections on glutamate decarboxylase, preproenkephalin and dopamine D2 receptor mRNAs in the adult rat striatumBrain Research, 1993
- D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal NeuronsScience, 1990
- Induction of chorea and dystonia in parkinsonian primatesMovement Disorders, 1990
- Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTPNeuroscience Letters, 1989
- cDNA sequence of human β-preprotachykinin, the common precursor to substance P and neurokinin AFEBS Letters, 1986
- Quantitative in situ hybridization histochemistry reveals increased levels of corticotropin-releasing factor mRNA after adrenalectomy in ratsNeuroscience Letters, 1986